Studies of Bio-path’s BP-1001-A show potential in obesity, diabetes
Dec. 20, 2024
Bio-path Holdings Inc. has conducted preclinical studies of BP-1001-A, a drug product modification of prexigebersen, confirming its effectiveness in affecting insulin signaling for the potential treatment of obesity and related metabolic diseases in type 2 diabetes patients.